Issue 127 • February 2023

Tracking the ups and downs of pharma deals 

Regulation starts to catch up with AI in pharma

High hopes for mRNA anti-cancer vaccines

In association with

CRISPR gene therapies cut through in 2023

The first approval decision for a CRISPR gene therapy in 2023 sets expectations for things to come

In association with

Issue 127

Brought to you by

02/24/2024 12:34:52
  • Home | CRISPR gene therapies cut through in 2023
  • In this issue
  • Contents
  • Mimotopes Company Insight
  • Tripletree
  • Briefing
  • Industry news
  • The pharma industry briefing
  • HOF Sonderanlagenbau
  • Owen Mumford Company Insight
  • Owen Mumford Aidaptus
  • Comment
  • High hopes for mRNA anti-cancer vaccines with early successes
  • Cell therapies might revolutionise treatment for multiple sclerosis patients
  • Downturn for top biopharma companies as Covid-19 vaccine demand falls in Q3
  • Inflation threatens supply of life-saving generics to Europe
  • Data is the key to a safer and more controlled pharmaceutical cold-chain
  • Molnar-Institute Company Insight
  • Molnar-Institute
  • In Depth
  • CRISPR gene therapies: Is 2023 a milestone year in the making?
  • Tracking the ups and downs of pharma deals
  • Regulation starts to catch up with AI in pharma
  • Next on trial diversity: Embracing participants with cognitive impairment
  • Digital twins: The next frontier to ease clinical trial conduct
  • CMO Moves: Regulatory catalysts for therapy manufacturing -January
  • Events
  • Next issue
01/19/2023 00:00:00